TreeFrog Therapeutics has raised $75 million in financing to support the clinical development of its stem cell-derived cell therapies for Parkinson’s disease, the company said in a press release. The new financing round, which brings the total funding to date to $83 million, will allow the company to use…
The Michael J. Fox Foundation (MJFF) has released a new suite of free educational resources that focuses on so-called “off” periods when Parkinson’s disease symptoms reappear or worsen as medications wear off. These new resources, available at michaeljfox.org/off, offer patients and their families tips for managing “off” time,…
The antioxidant urate failed to slow Parkinson’s disease progression in newly diagnosed patients over two years, according to data from a Phase 3 clinical trial. “While our study did not rule out a protective effect of urate in Parkinson’s, it clearly showed that increasing urate did not slow disease…
High prices, lack of access, and long waiting times are major barriers to people who want to undergo genetic testing for Parkinson’s disease, according to a survey by the International Parkinson and Movement Disorder Society (MDS). Survey results will be presented at the MDS Virtual Congress 2021, held…
The majority of Parkinson’s patients given Sunovion‘s Kynmobi (apomorphine hydrochloride) for “off” episodes during Phase 3 clinical trials did not require additional treatment for vomiting or nausea, the company said. Indeed, an analysis found that nearly 90% of participants reached the optimal dose of Kynmobi in trials without…
A newly launched five-year, $3 million collaboration, called ENIGMA-PD, will investigate brain imaging, genetics, and clinical data in a global study of Parkinson’s disease. Research efforts in more than 20 countries will be combined in the new project, created by the University of Southern California’s Mark and Mary…
The use of non-steroidal anti-inflammatory drugs (NSAIDs) seems to have no effect on the incidence of Parkinson’s disease, according to a large retrospective Norwegian study. Researchers focused on the NSAIDs prescribed most in Norway: diclofenac, ibuprofen, and naproxen. In the study “NSAID use is not associated with Parkinson’s…
A potential Parkinson’s therapy based on a protein with an ability to protect neurons — called recombinant (lab-made) human cerebral dopamine neurotrophic factor (rhCDNF) — has been transformed into tiny nanoparticles that may allow for its use as a nasal spray, Herantis Pharma,…
An artificial intelligence (AI) tool was able to distinguish, with great accuracy, Parkinson’s patients from healthy peers by analyzing short videos of facial expressions, particularly smiles, a small study shows. The predictive accuracy of the new tool was comparable to that of video analysis that uses motor tasks to…
Two investigational small molecules known as GT-02287 and GT-02329 lowered toxic protein levels in patient-derived cell models of Parkinson’s disease associated with a mutation in GBA1, their developer, Gain Therapeutics, announced. Gain is planning additional preclinical studies this year that could support applications to regulatory agencies allowing the compounds to…
Get regular updates to your inbox.
